|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.2636 - 0.2700|
|52 Week Range||0.2300 - 21.5000|
|Beta (3Y Monthly)||0.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 23, 2017 - Mar 24, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the company has entered into a definitive licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac), a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. In July, the Company announced that it has amended the protocol for the FOCUS trial, which is now enrolling as a single-arm, multi-center open label study. Safety data collected have not been modified as a result of the amendment, and safety data from both the randomized and single-arm protocols will be pooled in any analyses submitted to the Food & Drug Administration as part of a New Drug Application.
NEW YORK, Nov. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces.